Literature DB >> 18299540

Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease.

Christopher Patterson1, John W Feightner, Angeles Garcia, G-Y Robin Hsiung, Christopher MacKnight, A Dessa Sadovnick.   

Abstract

BACKGROUND: In addition to nonmodifiable genetic risk factors, potentially modifiable factors such as hypertension, hyperlipidemia and environmental exposures have been identified as risk factors for Alzheimer disease. In this article, we provide physicians with practical guidance on risk assessment and primary prevention of Alzheimer disease based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, held in March 2006.
METHODS: We developed evidence-based guidelines using systematic literature searches, with specific criteria for study selection and quality assessment, and a clear and transparent decision-making process. We selected studies published from January 1996 to December 2005 that met the following criteria: dementia (all-cause, Alzheimer disease or vascular dementia) as the outcome; longitudinal cohort study; study population broadly reflective of Canadian demographics; and genetic risk factors and general risk factors (e.g., hypertension, education, occupation and chemical exposure) identified. We graded the strength of evidence using the criteria of the Canadian Task Force on Preventive Health Care.
RESULTS: Of 3424 articles on potentially modifiable risk factors for dementia, 1719 met our inclusion criteria; 60 were deemed to be of good or fair quality. Of 1721 articles on genetic risk factors, 62 that met our inclusion criteria were deemed to be of good or fair quality. On the basis of evidence from these articles, we made recommendations for the risk assessment and primary prevention of Alzheimer disease. For the primary prevention of Alzheimer's disease, there is good evidence for controlling vascular risk factors, especially hypertension (grade A), and weak or insufficient evidence for manipulation of lifestyle factors and prescribing of medications (grade C). There is good evidence to avoid estrogens and high-dose (> 400 IU/d) of vitamin E for this purpose (grade E). Genetic counselling and testing may be offered to at-risk individuals with an apparent autosomal dominant inheritance (grade B). Screening for the apolipoprotein E genotype in asymptomatic individuals in the general population is not recommended (grade E).
INTERPRETATION: Despite the personal and societal burden of dementia, our understanding of genetic predisposition to dementias and the contribution of other risk factors remains limited. More importantly, there are few data to explain the overall risks and benefits of prevention strategies or their impact of risk modification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299540      PMCID: PMC2244657          DOI: 10.1503/cmaj.070796

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  53 in total

1.  Influence of leisure activity on the incidence of Alzheimer's disease.

Authors:  N Scarmeas; G Levy; M X Tang; J Manly; Y Stern
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

2.  Severe dementia. Prevalence and clinical features in a biracial US population.

Authors:  B S Schoenberg; D W Anderson; A F Haerer
Journal:  Arch Neurol       Date:  1985-08

3.  Mediterranean diet, Alzheimer disease, and vascular mediation.

Authors:  Nikolaos Scarmeas; Yaakov Stern; Richard Mayeux; Jose A Luchsinger
Journal:  Arch Neurol       Date:  2006-10-09

4.  Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias.

Authors:  B L Plassman; R J Havlik; D C Steffens; M J Helms; T N Newman; D Drosdick; C Phillips; B A Gau; K A Welsh-Bohmer; J R Burke; J M Guralnik; J C Breitner
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

5.  Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project.

Authors:  Hui-Xin Wang; Anita Karp; Bengt Winblad; Laura Fratiglioni
Journal:  Am J Epidemiol       Date:  2002-06-15       Impact factor: 4.897

6.  Full genome screen for Alzheimer disease: stage II analysis.

Authors:  Amanda Myers; Fabienne Wavrant De-Vrieze; Peter Holmans; Marian Hamshere; Richard Crook; Danielle Compton; Helen Marshall; David Meyer; Shantia Shears; Jeremy Booth; Dzanan Ramic; Heather Knowles; John C Morris; Nigel Williams; Nadine Norton; Richard Abraham; Pat Kehoe; Hywel Williams; Varuni Rudrasingham; Francis Rice; Peter Giles; Nigel Tunstall; Lesley Jones; Simon Lovestone; Julie Williams; Michael J Owen; John Hardy; Alison Goate
Journal:  Am J Med Genet       Date:  2002-03-08

Review 7.  Dietary factors and Alzheimer's disease.

Authors:  José A Luchsinger; Richard Mayeux
Journal:  Lancet Neurol       Date:  2004-10       Impact factor: 44.182

8.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

Authors:  C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

9.  Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia.

Authors:  L J Launer; K Andersen; M E Dewey; L Letenneur; A Ott; L A Amaducci; C Brayne; J R Copeland; J F Dartigues; P Kragh-Sorensen; A Lobo; J M Martinez-Lage; T Stijnen; A Hofman
Journal:  Neurology       Date:  1999-01-01       Impact factor: 9.910

10.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

Authors:  Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

View more
  65 in total

1.  AVR/NAVR deficiency lowers blood pressure and differentially affects urinary concentrating ability, cognition, and anxiety-like behavior in male and female mice.

Authors:  Victoria L M Herrera; Pia Bagamasbad; Julius L Decano; Nelson Ruiz-Opazo
Journal:  Physiol Genomics       Date:  2010-10-05       Impact factor: 3.107

2.  Sevoflurane impairs acquisition learning and memory function in transgenic mice model of Alzheimer's disease by induction of hippocampal neuron apoptosis.

Authors:  Zhen Jia; Lina Geng; Guanglun Xie; Qinjun Chu; Wei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  A brief update on dementia prevention.

Authors:  M C Polidori; L Pientka
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

Review 4.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  How applicable are clinical practice guidelines to elderly patients with comorbidities?

Authors:  Donatus R Mutasingwa; Hong Ge; Ross E G Upshur
Journal:  Can Fam Physician       Date:  2011-07       Impact factor: 3.275

6.  Interprofessional and integrated care of the elderly in a family health team.

Authors:  Ainsley Moore; Christopher Patterson; Joy White; Shelly T House; John J Riva; Kalpana Nair; Allison Brown; Amjed Kadhim-Saleh; David McCann
Journal:  Can Fam Physician       Date:  2012-08       Impact factor: 3.275

Review 7.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

8.  Hypoxia and Alzheimer disease.

Authors:  Sujoy Khan; Ioan B Davies
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

Review 9.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

10.  Predictors of progression of cognitive decline in Alzheimer's disease: the role of vascular and sociodemographic factors.

Authors:  Massimo Musicco; Katie Palmer; Giovanna Salamone; Federica Lupo; Roberta Perri; Serena Mosti; Gianfranco Spalletta; Fulvia di Iulio; Carla Pettenati; Luca Cravello; Carlo Caltagirone
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.